<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800150</url>
  </required_header>
  <id_info>
    <org_study_id>08076</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-08076</secondary_id>
    <secondary_id>CDR0000626148</secondary_id>
    <nct_id>NCT00800150</nct_id>
  </id_info>
  <brief_title>Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment</brief_title>
  <official_title>Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and Hematological Malignancies Who Are Not Eligible for Fully Myeloablative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of&#xD;
      chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It&#xD;
      may also stop the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune cells and help destroy any remaining cancer cells&#xD;
      (graft-versus-tumor effect).&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of total marrow and&#xD;
      total lymph node irradiation when given together with fludarabine and melphalan followed by&#xD;
      donor stem cell transplant in treating patients with advanced hematological cancer that has&#xD;
      not responded to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of intensity-modulated total marrow and lymph&#xD;
           node irradiation (TMLI) using helical tomotherapy in combination with a&#xD;
           reduced-intensity preparative regimen comprising fludarabine phosphate and melphalan in&#xD;
           patients undergoing allogeneic hematopoietic stem cell transplantation for advanced,&#xD;
           relapsed or refractory hematological malignancies.&#xD;
&#xD;
        -  To describe the toxicities of escalating doses of TMLI in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To describe the frequency of clinical response in patients treated with this regimen.&#xD;
&#xD;
        -  To describe the frequency of primary and secondary engraftment failure in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  To describe the time to neutrophil and platelet engraftment in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  To describe the incidence of acute and chronic graft-versus-host disease in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  To describe the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  To describe the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of intensity-modulated total marrow and lymph node&#xD;
      irradiation (TMLI).&#xD;
&#xD;
        -  Intensity-modulated radiation therapy: Patients undergo TMLI to skeletal bone/marrow,&#xD;
           major lymph node chains, spleen, and liver using helical tomotherapy twice daily on days&#xD;
           -6 to -3.&#xD;
&#xD;
        -  Reduced-intensity preparative regimen: Patients receive fludarabine phosphate IV on days&#xD;
           -6 to -2 and melphalan IV on day -1.&#xD;
&#xD;
        -  Hematopoietic stem cell transplantation (HSCT): Patients undergo allogeneic HSCT on day&#xD;
           0.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol objective could not be met. A new study with amended eligibility criteria will be&#xD;
    developed.&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of intensity-modulated total marrow and lymph node irradiation using helical tomotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of primary and secondary engraftment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft-versus-host disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>tomotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total marrow irradiation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total nodal irradiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
                    -  Intermediate- or high-risk disease&#xD;
&#xD;
               -  Myelofibrosis&#xD;
&#xD;
               -  Granulocytic sarcoma (chloroma)&#xD;
&#xD;
                    -  With or without bone marrow involvement&#xD;
&#xD;
               -  Mixed lineage leukemia&#xD;
&#xD;
                    -  Induction therapy must have been directed predominantly against AML&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Non-Hodgkin lymphoma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
          -  Relapsed or refractory disease with M3 marrow (marrow blasts &gt; 25%), meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Persistent disease after an induction attempt&#xD;
&#xD;
               -  Persistent initial disease after two induction attempts&#xD;
&#xD;
               -  Relapse after one re-induction attempt (second relapse)&#xD;
&#xD;
               -  Persistent disease after first relapse and initial re-induction attempt&#xD;
&#xD;
          -  Not eligible for myeloablative allogeneic hematopoietic stem cell transplantation due&#xD;
             to age (&gt; 50 years), organ insufficiency, or significant comorbidity&#xD;
&#xD;
               -  Patients 16-50 years of age must meet ≥ 1 of the following criteria:&#xD;
&#xD;
                    -  Ejection fraction 50-60% by MUGA scan and/or echocardiogram&#xD;
&#xD;
                    -  DLCO 50-75% of predicted&#xD;
&#xD;
                    -  Creatinine clearance or GFR 60-80 mL/min&#xD;
&#xD;
                    -  Serum bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
                    -  SGOT and SGPT 1.5-5 times upper limit of normal&#xD;
&#xD;
                    -  No other medical and/or psychosocial problem that, in the opinion of the&#xD;
                       primary physician or principal investigator, would place the patient at&#xD;
                       unacceptable risk from study regimen&#xD;
&#xD;
          -  No Fanconi anemia&#xD;
&#xD;
          -  HLA-identical sibling OR matched unrelated donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod or Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Able to lie supine in a full body cast for 30 minutes&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  No evidence of active hepatitis B or C infection&#xD;
&#xD;
          -  No evidence of cirrhosis&#xD;
&#xD;
          -  No uncontrolled viral, bacterial, or fungal infection within the past 4 weeks&#xD;
&#xD;
          -  No radiographic changes indicating pulmonary disease (e.g., pulmonary nodules,&#xD;
             infiltrates, or pleural effusion) unless cleared by pulmonary biopsy that shows no&#xD;
             evidence of active pulmonary disease&#xD;
&#xD;
          -  No major medical or psychiatric disorder that would seriously compromise patient&#xD;
             tolerance of study regimen&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Rosenthal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>November 27, 2008</study_first_submitted>
  <study_first_submitted_qc>November 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

